TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：82

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[31] Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, Kenneth K. W.
Fong, Winnie
Cho, William C. S.
FRONTIERS IN ONCOLOGY, 2021, 11
[32] Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib
Lin, Chien-Yu
Chang, Wei-Ting
Su, Po-Lan
Kuo, Chin-Wei
Yang, Jen
Lin, Chien-Chung
Lin, Sheng-Hsiang
JAMA NETWORK OPEN, 2024, 7 (12) : e2448364
[33] First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study
Cortot, Alexis B.
Madroszyk, Anne
Giroux-Leprieur, Etienne
Molinier, Olivier
Quoix, Elisabeth
Berard, Henri
Otto, Josiane
Rault, Isabelle
Moro-Sibilot, Denis
Raimbourg, Judith
Amour, Elodie
Morin, Franck
Hureaux, Jose
Moreau, Lionel
Debieuvre, Didier
Morel, Hugues
Renault, Aldo
Pichon, Eric
Huret, Benjamin
Charpentier, Sandrine
Denis, Marc G.
Cadranel, Jacques
CLINICAL CANCER RESEARCH, 2021, 27 (15) : 4168 - 4176
[34] Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
Jassem, Jacek
LANCET RESPIRATORY MEDICINE, 2018, 6 (11) : 808 - 810
[35] Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer
Kaneda, Toshihiko
Hata, Akito
Tomioka, Hiromi
Tanaka, Kosuke
Kaji, Reiko
Fujita, Shiro
Tomii, Keisuke
Katakami, Nobuyuki
LUNG CANCER, 2014, 86 (02) : 213 - 218
[36] Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET
Arvold, Nils D.
Heidari, Pedram
Kunawudhi, Anchisa
Sequist, Lecia V.
Mahmood, Umar
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2016, 15 (02) : 234 - 242
[37] Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR-mutant NSCLC: A Multicenter Study
Jiang, Tao
Cheng, Ruirui
Zhang, Guowei
Su, Chunxia
Zhao, Chao
Li, Xuefei
Zhang, Jie
Wu, Fegnying
Chen, Xiaoxia
Gao, Guanghui
Li, Wei
Cai, Weijing
Zhou, Fei
Zhao, Jing
Xiong, Anwen
Ren, Shengxiang
Zhang, Guojun
Zhou, Caicun
Zhang, Jun
CLINICAL LUNG CANCER, 2017, 18 (06) : 631 - +
[38] What new therapeutic targets exist for EGFR-mutant NSCLC?
Rosell, Rafael
LANCET ONCOLOGY, 2014, 15 (11) : 1184 - 1185
[39] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
Boussageon, Maxime
Swalduz, Aurelie
Perol, Maurice
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
[40] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Fukihara, Jun
Watanabe, Naohiro
Taniguchi, Hiroyuki
Kondoh, Yasuhiro
Kimura, Tomoki
Kataoka, Kensuke
Matsuda, Toshiaki
Yokoyama, Toshiki
Hasegawa, Yoshinori
ONCOLOGY, 2014, 86 (02) : 86 - 93

← 1 2 3 4 5 →